Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Percheron TherapeuticsPERCF 3-Year Book Growth Rate is -33.80% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 909 Drug Manufacturers companies, Percheron Therapeutics ranks worse than 93.62% on this metric.
During the past 12 months, Percheron Therapeutics's average Book Value per Share Growth Rate was -57.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -33.80% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -2.10% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -6.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Percheron Therapeutics was 64.20% per year. The lowest was -42.10% per year. And the median was -15.45% per year.
Percheron Therapeutics (OTCPK:PERCF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Percheron Therapeutics 3-Year Book Growth Rate Related Terms
PERCF vs ZTS: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Percheron Therapeutics 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Percheron Therapeutics's 3-Year Book Growth Rate falls into.
Percheron Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -33.80% mean?
Percheron Therapeutics (PERCF) has a 3-Year Book Growth Rate of -33.80% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Percheron Therapeutics and its competitors. According to the industry distribution chart, Percheron Therapeutics ranks #851 out of 909 companies in the Drug Manufacturers industry, placing it in the top 93.6%.
Is Percheron Therapeutics' 3-Year Book Growth Rate too high?
Percheron Therapeutics' current 3-Year Book Growth Rate is -33.80%. Based on the distribution chart, Percheron Therapeutics ranks #851 out of 909 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Percheron Therapeutics' 3-Year Book Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Percheron Therapeutics ranks #851 out of 909 companies for 3-Year Book Growth Rate. This places Percheron Therapeutics in the lower half of its industry. The industry median 3-Year Book Growth Rate is 4.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.70, based on 909 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Percheron Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Percheron Therapeutics's current 3-Year Book Growth Rate is -33.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (PERCF) has a current 3-Year Book Growth Rate of -33.80%. The current 3-Year Book Growth Rate is -33.80%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Percheron Therapeutics (PERCF), the current 3-Year Book Growth Rate is -33.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PERCF has been successfully added to your 
